###### What are the new findings?

-   A short bout of high-intensity exercise increased serum brain-derived neurotrophic factor (sBDNF) in a mild cognitive impairment (MCI) cohort.

-   While high-intensity interventions were feasible in this patient group, significant improvements were not observed in cognitive performance.

###### How might it impact on clinical practice?

-   Further research is needed to establish if acute exercises increase resting sBDNF concentration. However, exercise training may be a potential strategy to address the declining BDNF profile in an MCI population.

Introduction {#s1}
============

Mild cognitive impairment (MCI) is regarded as a clinical prodrome to Alzheimer's disease (AD) and other dementias, affecting approximately 15%--20% of people over the age of 65,[@R1] with 10%--15% of people with MCI progressing to dementia per year.[@R2] With the ongoing challenges in developing disease-modifying drugs, research into non-pharmacological strategies such as exercise, to prevent dementia or treat cognitive decline has gained increasing importance. A recent update to the American Academy of Neurology practice guideline on MCI now includes a recommendation for regular exercise as part of overall disease management.[@R3]

A significant body of work has investigated the effects of acute exercise on cognition. Meta-analytical reviews report an overall small positive effect on cognitive performance following acute exercise (mean effect 0.10--0.20), especially in areas of prefrontal cortex-dependent cognition.[@R4] However, the underlying neurobiological basis of these results has received less attention.

Brain-derived neurotrophic factor (BDNF), a member of the neurotrophin family, plays a predominant role in neuronal plasticity[@R7] and has been shown to decrease progressively with age,[@R8] with attenuated loss and a corresponding decrease in cognitive function in MCI cohorts compared with elderly controls.[@R10] Studies in both animal models and human subjects have described a number of neurobiological changes after an acute bout of exercise[@R13] and recent evidence postulates BDNF as a mediator of the acute exercise-cognitive relationship in healthy cohorts.[@R14]

The transitional phase of MCI along the cognitive continuum presents an opportunity for targeted interventions such as the exercise-induced upregulation of BDNF, which may help slow the rate of cognitive decline. As chronic exercise is the cumulative result of regular bouts of acute exercise, understanding the neurobiological effects of varying acute exercise paradigms is an integral part of building a comprehensive understanding of the long-term effects of exercise on cognitive function.[@R13] This information will help determine the optimal prescription of acute and chronic exercise and add to the emerging research that supports the role of exercise as a natural therapeutic tool to treat cognitive decline in older adults with MCI.

The aim of this study was to examine the effect of a short bout of high-intensity aerobic exercise on serum BDNF (sBDNF) and cognitive performance in individuals with MCI. The working hypothesis was that a short bout of high-intensity exercise would significantly increase sBDNF and cognitive performance compared with a resting control condition.

Methods {#s2}
=======

Study Design {#s2-1}
------------

Participants were randomised to one of two testing schedules ([figure 1](#F1){ref-type="fig"}) using a computer-generated randomisation list generated by a researcher independent of the study. Treatment allocation was concealed from the investigator. Group A represented the exercise condition while group B was designed to act as the control condition. Outcome measurements were collected at T1 (baseline) and T2 (after the exercise condition in group A and after a resting control condition for group B), with T3 measurements (after exercise) only collected in group B.

![Study design and schedule of outcome assessments.](bmjsem-2018-000499f01){#F1}

Patient and Public Involvement (PPI) {#s2-2}
------------------------------------

As no funds or time were allocared for PPI, participants were unable to be involved in study design stages. However, participants have been involved in the dissemination.

Participants {#s2-3}
------------

### Inclusion and exclusion criteria {#s2-3-1}

Participants were screened and recruited from a network of memory clinics (n=38) and through community recruitment (n=26).[@R15] Details of the study inclusion and exclusion criteria have been published in the NeuroExercise study protocol.[@R16] To summarise, participants had a diagnosis of amnestic MCI due to AD according to the National Institute on Aging and Alzheimer's Association criteria,[@R17] scored 18--26 on the Montreal Cognitive Assessment (MoCA)[@R18] and were classified as having memory decline but not dementia (Clinical Dementia Rating global score=0.5). Participants met the following inclusion criteria: ECG without significant abnormalities, and medical clearance to undergo a symptom-limited cardiopulmonary exercise test (CPET). Participants were deemed ineligible if they had a diagnosis of AD or other type of dementia; any major psychiatric disorder; unstable cardiac, renal, lung, liver or other severe chronic disease; or engagement in moderate-intensity aerobic exercise training for more than 30 min, three times per week, during the past 2 years.

Study outcomes {#s2-4}
--------------

Data collection and study interventions were conducted at the Wellcome Trust-Health Research Board Clinical Research Facility in Dublin. Ethical approval was granted from Tallaght Hospital and St James' Hospital Joint Research and Ethics Committee (REC) and the RECs of referring sites. Due to limited study personnel, the outcome assessor was not blinded to intervention group. All study outcomes were collected in a non-fasting state between the hours of 09:00 and 15:00.

### Blood sampling {#s2-4-1}

Participants completed a 10 min resting period prior to baseline blood sampling (T1), with postintervention blood samples collected within a 10 min period following each experimental condition. Serum collection tubes were inverted five times and allowed to coagulate at room temperature before being centrifuged at 1300×*g* for 10 min at 4°C. The resulting serum was removed, aliquoted and stored at −80°C pending laboratory analysis. Samples and standards were analysed using commercially available BDNF DuoSet ELISA development systems kit (R&D Systems Europe, Oxon, UK) in accordance with the manufacturer's instruction. Standard curve was constructed and concentration of BDNF in samples was calculated by extrapolation from these curves with results expressed in pg/mL.

### Cognitive performance {#s2-4-2}

Cognitive tests were administered as per standardised test instructions and included the Cambridge Neuropsychological Test Automated Battery (CANTAB) Paired Associates Learning (PAL) task, a measure of visuospatial learning and memory which was considered the primary cognitive outcome. CANTAB PAL is regarded as a visuospatial memory task, highly sensitive to the memory impairments characteristic in prodromal AD that assesses visual memory and new learning through the testing of conditional learning of pattern--location associations.[@R19] The Sustained Attention to Response Task (SART), a computerised Go-No-Go paradigm measuring sustained attention, and the Stroop Neuropsychological Screening Test (Stroop) measuring executive function were measured as secondary cognitive outcomes. Testing took approximately 30 min to complete.

### Intervention {#s2-4-3}

Participants performed a graded CPET to volitional exhaustion as per WHO protocol.[@R20] The test was performed on a standard COSMED cycle ergometer with oxygen consumption (VO~2~) measured using the K4B2^2^ equipment (K4B2^2^ User Manual, COSMED, Italy). ECG and blood pressure measurements were collected at rest and for the duration of the test. The protocol commenced with a 3 min warm-up of unloaded cycling followed by an incremental phase of cycling exercise during which the load increased by 25 W every 2 min until the test was terminated and a 3 min cool down period was performed. The test was terminated when three of the following criteria were met: clinical signs of exhaustion, respiratory quotient ≥1.10, reaching within 10 beats of the predicted heart rate max (220 age) or flattening of the VO~2~ uptake curve (≤110 mL increase during the last minute). The control condition in group B consisted of 30 min lying in a semirecumbent position.

### Sample size {#s2-4-4}

A recent meta-analytical review reported that an acute bout of exercise increased BDNF levels with a moderate effect size (Hedges' g=0.46, SE=0.08, 95% CI 0.29 to 0.62, z=5.49, p\<0.001).[@R21] Using these values, with 0.05 significance level and 80% power, 32 participants were required per arm to demonstrate an effect size of 0.46 in people with MCI.

Statistical analysis {#s2-5}
--------------------

SPSS V.24 (SPSS) was used for analysis with statistical significance set at p\<0.05. Kolmogorov-Smirnov test (p\>0.05) and visual inspection of histogram and Q-Q plots were used to assess assumptions of normality on all baseline variables. In the case of non-normally distributed data, non-parametric tests were performed.

To standardise baseline data, BDNF data were examined for outliers, with measurements ±2 SDs removed from the mean excluded as per standard approach.[@R22] Following these criteria, n=9 were removed from further analysis. Second, relative change (%) in BDNF was reported consistent with published reports.[@R23]

For the primary analysis of study outcomes, between-group differences between T1 and T2 were analysed using an independent samples t-test for normally distributed data and using a Mann-Whitney U test for non-normally distributed data. In the secondary analysis, Friedman's test and analysis of variance were used to measure the change over time in study outcomes in group B. Wilcoxon signed-rank tests and paired sample t-tests were performed in post hoc analysis to determine the effect size and compare T1--T2, T2--T3 and T1--T3 in group B. As secondary analysis involved multiple comparisons, a Bonferroni correction was applied and alpha level was revised to 0.025. An exploratory analysis of sex differences in BDNF and cognition was performed.

Results {#s3}
=======

Participants were enrolled from 25 February 2016 and data collection for this study ended on 17 July 2017. Sixty-four participants were enrolled and randomised to group A (n=35) or group B (n=29). Missing data included PAL at T1 (participant refusal to complete n=1), SART at T1 (measurement error n=1), missed venepuncture at T2 (n=1) and invalid Stroop T1--T3 (colour blindness n=2, incomplete record sheet n=2). Missing data were treated as missing at random and each missing observation removed from analysis.

Participant characteristics {#s3-1}
---------------------------

Participant characteristics (age, sex, education, MoCA and body mass index) were similar between groups at baseline ([table 1](#T1){ref-type="table"}). Participants had a mean age of 70.5 (±6.3) years, 53.2% female, mean MoCA score of 22.0 (±2.5) and the majority (n=38, 59.4%) were highly educated (\>13 years). Cardiorespiratory (CR) fitness levels categorised based on age and gender norms revealed a large proportion (n=54, 84.4%) were categorised as very poor (\<20th percentile).[@R25] Despite randomisation, CR fitness calculated using results of the CPET was significantly higher in group B (21.35±4.85 mL/kg/min) compared with group A (17.77±5.15 mL/kg/min).

###### 

Participant demographics by study group

  -------------------------------------------------------------------------
  Variable               Group A: Exercise\   Group B: Control\   P value
                         n=35                 n=29                
  ---------------------- -------------------- ------------------- ---------
  Gender (M/F)           13/22                17/12               0.14

  Age (years)            71.7 (5.3)           69.0 (7.2)          0.09

  Education (years)      12.5 (3.0)           14.0 (3.2)          0.07

  MoCA                   21.6 (2.5)           22.4 (2.6)          0.24

  BMI (kg/m^2^)          27.44 (4.49)         26.14 (4.21)        0.23

  VO~2~max (mL/kg/min)   17.77 (5.15)         21.35 (4.85)        0.002\*
  -------------------------------------------------------------------------

Data are presented as mean±SD for normally distributed data and as median ±IQR for non-normally distributed data. Note statistical significance.

\*P\<0.05.

BDI, body mass index; MoCa, Montreal Cognitive Assessment; VO~2~, oxygen consumption.

There were no significant between-group differences in baseline measures of cognitive performance or sBDNF. Baseline sBDNF did not correlate with MoCA (r=0.10, p=0.46), Paired Associates Learning Total Errors Adjusted (PALTEA) (r=0.10, p=0.44) or age (r=−0.02, p=0.87). Baseline and postexercise BDNF did not correlate with CR fitness (VO~2~ max) (baseline r=−0.01, p=0.92; postexercise r=0.01, p=0.89). Baseline sBDNF concentration for male (Md 3699.52±6758.59 pg/mL^1^) and female (Md 5058.11±6280.08 pg/mL^1^) participants was comparable (p=0.224). Measurements of duration and intensity in the exercise condition did not show any significant between-group differences ([table 2](#T2){ref-type="table"}). There were no adverse events.

###### 

Measurement parameters of exercise intensity and duration in the exercise condition for both groups

                                     Group A n=35    Group B n=29    P value
  ---------------------------------- --------------- --------------- ---------
  Time (min:s)                       09:11 (03:63)   10:25 (02:26)   0.11
  Max watts (W~max~)                 100 (50)        100 (50)        0.34
  Max HR (HR~max~)                   118 (20)        124 (21)        0.27
  Peak lactate (mmol/L)              5.0 (4.8)       4.4 (2.7)       0.16
  Lactate change (mmol/L)            2.9 (3.5)       2.8 (3.5)       0.33
  Respiratory exchange ratio (RER)   1.06 (0.12)     1.06 (0.07)     0.95

Primary analysis {#s3-2}
----------------

### Between-group difference in BDNF and cognitive performance {#s3-2-1}

sBDNF concentration increased in group A (exercise condition) from T1 (Md 4564.61±5737.23 pg/mL^1^) to T2 (Md 5173.27±5997.54 pg/mL^1^) and decreased in group B (resting control condition) from T1 (Md 4593.74±9558.29 pg/mL^1^) to T2 (Md 3974.66±3668.22 pg/mL^1^) (p=0.024, Effect Size (ES)=0.3) ([figure 2](#F2){ref-type="fig"}). The median % relative change in sBDNF from T1 to T2 in response to exercise in group A was 7.07% (±31.30%) and −13.3% (±22.49%) in response to a resting control condition in group B (p=0.06).

![Boxplot showing between-group difference in serum BDNF (sBDNF) in response to a high-intensity exercise or resting control condition.](bmjsem-2018-000499f02){#F2}

Surprisingly, SART commission error rate increased in group A (Md 0.50, n=34) and decreased in group B (Md −1.0, n=29) from T1 to T2, U=654.000, z=2.240, r=0.28. An acute bout of high-intensity exercise did not significantly alter PALTEA, Stroop colour word score (CWS) or SART reaction time (RT) ([table 3](#T3){ref-type="table"}).

###### 

Effect of exercise on BDNF and cognitive outcomes

  Variables                        Baseline (T1)         Follow-up (T2)      Change within group   P value   Effect size
  -------------------------------- --------------------- ------------------- --------------------- --------- -------------
  BDNF (pg/mL)                                                                                               
   Exercise                        4642.51 (7065.08)     5308.17 (6355.73)   123.96 (2690.97)      0.07      n/a
   Control                         5330.86 (10 346.65)   4477.95 (5002.88)   −530.79 (1427.44)               
  BDNF (pg/mL) outliers excluded                                                                             
   Exercise                        4564.61 (5737.23)     5173.27 (5997.54)   135.86 (1709.74)      0.024\*   0.3
   Control                         4593.74 (9558.29)     3974.66 (3668.22)   −530.79 (838.43)                
  CANTAB PALTEA                                                                                              
   Exercise                        44 (30)               46 (23)             .26 (10.29)           0.08      n/a
   Control                         44 (22)               33 (29)             −6 (15.3)                       
  Stroop CWS                                                                                                 
   Exercise                        66.42 (28.51)         70.48 (30.66)       4.00 (16.00)          0.456     n/a
   Control                         75.25 (26.97)         77.93 (27.42)       1.00 (13.00)                    
  SART commission errors                                                                                     
   Exercise                        2.5 (5)               4 (4)               0.5 (5)               0.025\*   0.28
   Control                         3 (4)                 2 (3)               −1 (3)                          
  SART reaction time (ms)                                                                                    
   Exercise                        142.04 (83.50)        128.07 (74.42)      4.84 (39.24)          0.055     n/a
   Control                         154.57 (78.90)        123.61 (79.62)      27.66 (51.36)                   

Primary analysis: Between-group differences T1 and T2 time points. Data are presented for the exercise (group A) and control group (group B) as mean±SD for normally distributed data and as median±IQR for non-normally distributed data. P value represents within-group differences with statistical significance.

\*P\<0.05.

BDNF, brain-derived neurotrophic factor; CWS, colour word score; PALTEA, Paired Associates Learning Total Errors Adjusted; SART, Sustained Attention to Response Task; n/a, not applicable.

Secondary analysis {#s3-3}
------------------

### Change over time within group B {#s3-3-1}

Repeated measures analysis within group B indicated a statistically significant difference in sBDNF across the three time points (p=0.005). sBDNF reduced significantly during the resting condition between T1 (Md=4593.74±9558.29 pg/mL^1^) and T2 (Md=3974.66±3668.22 pg/mL^1^) (p=0.01, r=0.38), and increased significantly from T2 (Md=3974.66±3668.22 pg/mL^1^) to T3 following completion of a short bout of high-intensity aerobic exercise (Md=4790.90±6713.17 pg/mL^1^) (p=0.001, r=0.48). The relative change in sBDNF is consistent with the findings of the primary analysis, with the mean % relative change in sBDNF concentration from T2 to T3 (postexercise) in group B of 15.7% (±22.1%).

Stroop CWS (Wilks' lambda=0.668, *F*(2,26)=6.461, p=0.005, multipartial η^2^=0.33) and SART RT (2, n=29)=0.036, p=0.005) changed significantly over time within group B. There were significant increases in Stroop CWS following participation in the exercise condition from T1 (M=75.25±26.97) to T3 (M=83.93±21.47) (mean increase=−8.67, 95% CI −13.55 to −3.80) (p=0.001, ES 0.34), indicating improved performance. SART RT reduced significantly in response to the control condition from T1 (Md 154.57 ms±78.90 ms) to T2 (Md 123.61 ms±79.62 ms) (p=0.004, ES 0.37), with no significant change in SART commission errors. Additionally, PALTEA did not change significantly over time (2, n=29)=7.000, p=0.03) although a non-significant decrease in error rate was observed from T1 (Md 44±22) to T2 (Md 33±29) (z=−2.130, p=0.03, ES 0.27) and from T1 to T3 (Md=28±30) (z=−2.232, p=0.026, ES 0.29). Results are presented in [table 4](#T4){ref-type="table"}.

###### 

Secondary analysis measuring change over time in study outcomes within group B

  Variables                        Baseline T1         Postcontrol condition T2   Postexercise condition T3   P value
  -------------------------------- ------------------- -------------------------- --------------------------- ---------
  BDNF (pg/mL) outliers excluded   4593.74 (9558.29)   3974.66 (3668.22)          4790.90 (6713.17)           0.005\*
  CANTAB PALTEA                    44 (22)             33 (29)                    28 (30)                     0.03
  Stroop CWS                       75.25 (26.97)       77.93 (27.42)              83.93 (21.47)               0.005\*
  SART commission errors           3 (4)               2 (3)                      2 (3)                       0.25
  SART reaction time (ms)          154.57 (78.90)      123.61 (79.62)             142.07 (65.87)              0.005\*

P value represents within group change over time with statistical significance.

Bonferroni correction applied and alpha level \*P\<0.025.

BDNF, brain-derived neurotrophic factor; CWS, colour word score; PALTEA, Paired Associates Learning Total Errors Adjusted; SART, Sustained Attention to Response Task.

### Sex differences in acute exercise BDNF and cognitive response {#s3-3-2}

There was a significant difference in SART RT pre-to-post exercise in female participants (Pre Md 156.14 ms±83.31 ms to post Md 134.62 ms±69.86 ms) compared with male participants (Pre Md 130.08 ms±76.45 ms to post Md 136.77 ms±67.56 ms) (p=0.025, ES 0.28). There were no significant differences between male and female participants in exercise BDNF response and other cognitive measures.

Discussion {#s4}
==========

This study examined the changes in sBDNF concentration and cognitive performance in response to a short bout of high-intensity aerobic exercise in individuals with MCI. To the best of our knowledge, this is the first study to show that a short bout of high-intensity aerobic exercise increases peripheral sBDNF in a population with MCI. The results support previous work in this area which has primarily focused on young healthy cohorts.[@R22] However, in the current study secondary analysis demonstrated only modest within-group post exercise cognitve change.

The findings of the present study are consistent with previous studies that have reported increases in peripheral BDNF in response to acute exercise protocols in healthy adult cohorts[@R22] and in clinical populations.[@R34] To date, few studies have examined the effect of acute aerobic exercise on peripheral BDNF in older adults[@R36] or MCI.[@R41] However, a recent study by Tsai *et al*[@R41] found an acute bout of 30 min of moderate-intensity aerobic exercise significantly increased sBDNF levels in a group (n=25) of older adults with amnestic MCI. In agreement, our findings indicate that older adults with MCI, despite being in the early stages of the neurodegenerative process, retain the ability to increase peripheral BDNF concentration following acute aerobic exercise of varying intensity and duration.

Across the literature, the % BDNF change in response to exercise varies widely in healthy and clinical populations, with an average increase of 60% reported in peripheral BDNF levels following acute exercise.[@R23] The magnitude of BDNF change in response to exercise is dependent on blood lactate concentration, duration and intensity of exercise and is transient in nature.[@R23] The within-group sBDNF change in response to exercise observed in our results was 7.07% (group A) and 15.7% (group B). Studies of similar study design that examined comparable graded exercise protocols in healthy young cohorts[@R22] and clinical populations[@R36] reported higher % BDNF change in response to exercise (16%--30% relative change from baseline). Coelho *et al*[@R36] examined the exercise BDNF response in 21 older adults with AD and 18 healthy older adults and found significant increases in BDNF plasma levels in both groups (p=0.001; *F*=13.63; df=37) with a relative change of 22% and 16%, respectively. Despite comparable performance of the exercise condition (duration and intensity) in both groups, group B demonstrated a higher % increase in sBDNF after exercise. In contrast to existing literature, the BDNF upregulation did not appear to be driven by lactate[@R45] but may be explained by the significantly higher CR fitness observed in group B.

CR fitness in the present study cohort was low, with n=59 (92.2%) of participants categorised as very poor (\<20th percentile) or poor (20th--40th percentiles).[@R25] While evidence supports strong associations between higher levels of CR fitness and cognitive function,[@R47] the relationship between BDNF and CR fitness is unclear, with some studies reporting a positive association between the two immediately after exercise[@R49] and others reporting an inverse relationship.[@R50] A meta-analytical review by Dinoff *et al*[@R42] reported significant associations between VO~2~ peak and effect sizes in studies measuring the effects of acute exercise on BDNF, indicating greater increases in peripheral BDNF after acute exercise in those with greater CR fitness. In the present study, we could not compare BDNF response in high and low-fit participants due to the homogeneity in the study sample but no correlation was found between CR fitness (V0~2~ max) and baseline sBDNF levels.

Despite the consistently reported positive effects of acute exercise on cognitive performance,[@R14] the findings of the current study do not support the beneficial effect of acute exercise on cognitive performance in MCI. In contrast, the resting control condition demonstrated a decrease in sBDNF and improved performance on the SART, a task that activates the cortical and subcortical attentional networks.[@R56] While it is possible that the resting control condition may have reduced circulating cortisol levels similar to quiet meditation practice,[@R57] the mechanisms underpinning the observed effect cannot be fully explained with further research required.

Recent meta-analytical reviews report that the BDNF and cognitive response to exercise may vary in a sex-dependent manner.[@R42] Subgroup analysis by Dinoff *et al*[@R42] revealed significant increase in BDNF after acute exercise in males but not in females. In contrast, our findings did not reveal sex differences in BDNF response to acute exercise. However, we did observe sex differences in SART RT with females gaining significant improvement in RT following acute exercise compared with males. RTs are known to slow and become more variable with age, with significant sex differences reported in RT variability.[@R60] Despite recent reports of sex differences in the cognitive response in executive function tasks to exercise,[@R59] we did not observe any sex differences in other cognitive measures in response to acute exercise.

The results of the present study should be viewed in the context of a number of potential limitations. First, peripheral measurement of BDNF is not without limitations, as processes occurring centrally in the brain may not have a measurable influence on peripheral blood markers; nor may circulating BDNF have any influence on brain function within the time frame of this experiment. Second, secondary analysis of change in cognitive performance (group B) demonstrated improvement in executive function after exercise. However, group B completed an additional measurement of cognitive measures (T3), thereby increasing the risk of type I error due to practice effects of repeated tests which may be an important confounder of these results.[@R61] Finally, other factors that may mediate BDNF response to exercise were not examined. The BDNF val66met polymorphism, a genetic variant that occurs in 33% of the population, and the apolipoprotein E gene ε4 allele, the most prevalent genetic risk factor for late-onset AD, affect the expression of BDNF,[@R62] alter susceptibility to neuropathology and may be an important consideration in understanding responders to exercise.[@R63]

Conclusions {#s5}
===========

The results of this study indicate that a single session of high-intensity exercise is feasible in an MCI cohort, enhances circulating sBDNF concentration but does not improve visuospatial learning and memory, sustained attention or executive function. This research adds to the literature which postulates that the impaired BDNF profile in MCI cohorts may be amenable to exercise training as a strategy to address the declining BDNF profile.
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